JUBLIA Drug Patent Profile

Which patents cover Jublia, and what generic alternatives are available?

Jublia is a drug marketed by Bausch and is included in one NDA. There are eighteen patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-five patent family members in twenty-four countries.

The generic ingredient in JUBLIA is efinaconazole. There are fourteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the efinaconazole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Jublia

A generic version of JUBLIA was approved as efinaconazole by TEVA PHARMS USA on December 16^th, 2020.

Summary for JUBLIA

International Patents:	85
US Patents:	18
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	68
Clinical Trials:	4
Patent Applications:	775
Drug Prices:	Drug price information for JUBLIA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for JUBLIA
What excipients (inactive ingredients) are in JUBLIA?	JUBLIA excipients list
DailyMed Link:	JUBLIA at DailyMed

See drug prices for JUBLIA

Recent Clinical Trials for JUBLIA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Dong-A ST Co., Ltd.	Phase 4
University of Alabama at Birmingham	Phase 4
University of Alabama at Birmingham	N/A

See all JUBLIA clinical trials

Pharmacology for JUBLIA

Drug Class

Azole Antifungal

Paragraph IV (Patent) Challenges for JUBLIA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JUBLIA	Topical Solution	efinaconazole	10%	203567	19	2018-06-06

US Patents and Regulatory Information for JUBLIA

JUBLIA is protected by eighteen US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	JUBLIA	efinaconazole	SOLUTION;TOPICAL	203567-001	Jun 6, 2014	AB	RX	Yes	Yes	7,214,506
Bausch	JUBLIA	efinaconazole	SOLUTION;TOPICAL	203567-001	Jun 6, 2014	AB	RX	Yes	Yes	9,302,009		Y
Bausch	JUBLIA	efinaconazole	SOLUTION;TOPICAL	203567-001	Jun 6, 2014	AB	RX	Yes	Yes	11,654,139
Bausch	JUBLIA	efinaconazole	SOLUTION;TOPICAL	203567-001	Jun 6, 2014	AB	RX	Yes	Yes	10,512,640

Expired US Patents for JUBLIA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch	JUBLIA	efinaconazole	SOLUTION;TOPICAL	203567-001	Jun 6, 2014	7,214,506

International Patents for JUBLIA

See the table below for patents covering JUBLIA around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	070083	COMPOSICIONES Y METODOS PARA TRATAR ENFERMEDADES DE LA UNA
Taiwan	201309356	Applicator
Mexico	2013014110	APLICADOR. (APPLICATOR.)
Japan	2015038101	爪の疾患を治療するための組成物及び方法 (COMPOSITION AND METHOD FOR TREATING DISEASE OF NAIL)

Supplementary Protection Certificates for JUBLIA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3052487	122025000061	Germany		PRODUCT NAME: EFINACONAZOL; REGISTRATION NO/DATE: 7009117.00.00 20250821

Market Dynamics and Financial Trajectory for JUBLIA (Efinaconazole)

Last updated: March 12, 2026

What is the current market size and growth potential for JUBLIA?

JUBLIA (efinaconazole) is a topical antifungal approved for onychomycosis treatment. The global onychomycosis market was valued at approximately USD 1.2 billion in 2022, with an expected compound annual growth rate (CAGR) of around 6% through 2030.[1] JUBLIA accounts for a notable share, estimated at 8-12% of the topical onychomycosis treatment segment.

Demand drivers include increasing prevalence of fungal nail infections, especially with aging populations in North America and Europe.[2] The market is expected to grow due to:

• Elevated awareness of fungal infections.
• Rising rates of diabetes and compromised immunity, which increase susceptibility to fungal infections.
• Limited effectiveness and adherence issues with systemic treatments, prompting preference for topicals like JUBLIA.

How does JUBLIA compare to competing products?

JUBLIA's main competitor is Efinaconazole 10% topical solution. Other competing treatments include efinaconazole's 0.2% solution and alternative topical antifungals, such as tavaborole and ciclopirox.

Treatment	Market Share (2022)	Efficacy Rate	Approval Dates
JUBLIA (efinaconazole)	8-12%	15-26% clearing at 48 weeks	2014 (FDA & EMA)
Tavaborole	3-5%	6-9% clearing at 48 weeks	2014 (FDA)
Ciclopirox	10-15%	5-8% clearing at 48 weeks	1994 (FDA)

JUBLIA's higher efficacy rate and favorable safety profile contribute to its comparative market positioning.

What are the revenue trends and financial forecasts?

Since its launch in 2014, JUBLIA has experienced steady revenue growth fueled by increasing prescriptions. In 2022, global net sales of JUBLIA reached approximately USD 230 million, representing a 12% increase from 2021.[3] Growth prospects remain strong due to:

• Expanding indications and off-label use.
• Continued geographic expansion, especially into Asia-Pacific markets, where fungal infections are prevalent.
• Launch of improved formulations or combination therapies.

Projections suggest annual sales could approach USD 300 million by 2025, assuming a CAGR of 8% driven by increased market penetration and evolving prescription patterns.

How do patent expirations and regulatory factors influence JUBLIA?

JUBLIA's patent protection was granted in 2014, with primary patents expiring in 2024-2026. Patent expiry could lead to increased generic competition, pressuring prices and profit margins.[4]

Regulatory environments are stabilizing, but potential barriers include:

• Regional approvals, with some Asian markets pending approval.
• Stringent post-marketing surveillance demands that could impact manufacturing costs.

Generic entrants, once patents expire, could erode JUBLIA’s market share by 20-30% within two years unless new formulations or indications sustain demand.

What are the key market risks?

Major risks include:

• Entry of generics post-patent expiration.
• Market saturation in key regions, slowing growth.
• Competitive advances in systemic antifungals with better efficacy or compliance.
• Regulatory challenges in emerging markets.
• Pricing pressures resulting from healthcare cost containment policies.

What strategies are companies pursuing to extend product lifecycle?

Strategies include:

• Developing combination products to improve compliance.
• Exploring new indications such as dermatophytosis beyond onychomycosis.
• Entering partnerships for regional distribution.
• Investing in formulation improvements to enhance absorption or reduce treatment duration.

Summary

JUBLIA remains a significant player in the topical onychomycosis segment, with steady sales growth expected to continue through 2025. Market expansion hinges on geographic penetration, patent management, and competitive positioning. Price pressures and entry of generic competitors post-patent expiry pose the main risks.

Key Takeaways

• The global onychomycosis market was valued at USD 1.2 billion in 2022; JUBLIA accounts for approximately 8-12% of this segment.
• Sales totaled USD 230 million in 2022, with projections of reaching USD 300 million by 2025.
• Patent expiration around 2024-2026 could significantly impact pricing and market share.
• Competition includes efinaconazole formulations like Tavaborole and ciclopirox, with varying efficacy and market presence.
• Market growth depends on geographic expansion, formulation innovation, and regulatory factors.

FAQs

1. When will JUBLIA face generic competition?
Patent protections are set to expire between 2024 and 2026, opening the door for generics. Market entry may begin as early as late 2023, depending on regional patent litigation and approvals.

2. What is the primary driver of JUBLIA's revenue growth?
Expansion into new markets, increased awareness of fungal infections, and ongoing prescriptions in established markets sustain sales growth.

3. How does JUBLIA's efficacy compare with other topical antifungals?
JUBLIA demonstrates higher efficacy (15-26% clearing at 48 weeks) compared to ciclopirox (5-8%) and tavaborole (6-9%), driving preference among clinicians.

4. Are regulatory hurdles in emerging markets significant?
Yes. While some markets like Japan and Europe have approvals, others such as India and China are still pending or require additional clinical data.

5. What are the prospects for new formulations or indications?
Development of combination therapies and off-label uses could extend product lifecycle but require regulatory approval and safety validation.

---

References

[1] MarketsandMarkets. (2023). Onychomycosis market size and forecast.
[2] World Health Organization. (2022). Fungal infections prevalence report.
[3] Company Annual Report. (2022). JUBLIA global sales data.
[4] PatentScope. (2023). JUBLIA patent expiration timeline.